<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": Research Article Sensitivity of a Ribavirin Resistant Mutant of" exact="Hepatitis" post="C Virus to Other Antiviral Drugs HCV Cross Resistance"/>
 <result pre="of Hepatitis C Virus to Other Antiviral Drugs HCV Cross" exact="Resistance" post="to Ribavirin and Other Drugs MihalikKathleen B.FeigelstockDino A.*[], Division"/>
 <result pre="to Ribavirin and Other Drugs MihalikKathleen B.FeigelstockDino A.*[], Division of" exact="Viral" post="Products, Center for Biologics Evaluation and Research, FDA, Bethesda,"/>
 <result pre="While ribavirin mono-therapy regimens have minimal effect on patients with" exact="chronic hepatitis" post="C virus (HCV) infections, they can be efficacious when"/>
 <result pre="ribavirin mono-therapy regimens have minimal effect on patients with chronic" exact="hepatitis" post="C virus (HCV) infections, they can be efficacious when"/>
 <result pre="high concentrations of 5-Fluorouracil and to parental levels in the" exact="absence of" post="the drug. Sequence of its genome shows that HCV-5FU"/>
 <result pre="to levels similar to parental virus when grown in the" exact="absence of" post="5-Fluorouracil. Funding This work was supported by internal funding"/>
 <result pre="decision to publish, or preparation of the manuscript. page-count: Introduction" exact="Hepatitis" post="C virus (HCV) is an enveloped, positive strand RNA"/>
 <result pre="of a polyprotein precursor that is cleaved by cellular and" exact="viral" post="proteases into 10 proteins (core, E1, E2, p7, NS2,"/>
 <result pre="NS4b, NS5a, and NS5B) (reviewed in reference [1]). Human HCV" exact="infection" post="causes chronic liver disease, cirrhosis, and is associated with"/>
 <result pre="and NS5B) (reviewed in reference [1]). Human HCV infection causes" exact="chronic" post="liver disease, cirrhosis, and is associated with hepatocellular carcinoma"/>
 <result pre="NS5B) (reviewed in reference [1]). Human HCV infection causes chronic" exact="liver disease," post="cirrhosis, and is associated with hepatocellular carcinoma [2]. It"/>
 <result pre="infection causes chronic liver disease, cirrhosis, and is associated with" exact="hepatocellular carcinoma" post="[2]. It is estimated that 180 million people worldwide"/>
 <result pre="causes chronic liver disease, cirrhosis, and is associated with hepatocellular" exact="carcinoma" post="[2]. It is estimated that 180 million people worldwide"/>
 <result pre="people worldwide are infected with HCV [3] and given the" exact="chronic" post="nature of the infection it is expected that the"/>
 <result pre="with HCV [3] and given the chronic nature of the" exact="infection" post="it is expected that the number of patients with"/>
 <result pre="infection it is expected that the number of patients with" exact="hepatocellular carcinoma" post="will increase in the coming years. The standard therapy"/>
 <result pre="it is expected that the number of patients with hepatocellular" exact="carcinoma" post="will increase in the coming years. The standard therapy"/>
 <result pre="of interferon, an interferon-free regimen for the treatment of HCV" exact="infections" post="is highly desirable. Recent studies have shown that ribavirin"/>
 <result pre="[13]. 5-Fluorouracil is broadly used in the clinic to treat" exact="cancer" post="[14] including HCV associated hepatocellular carcinoma [15]. 5-Fluorouracil displays"/>
 <result pre="in the clinic to treat cancer [14] including HCV associated" exact="hepatocellular carcinoma" post="[15]. 5-Fluorouracil displays mutagenic activity leading to viral extinction"/>
 <result pre="the clinic to treat cancer [14] including HCV associated hepatocellular" exact="carcinoma" post="[15]. 5-Fluorouracil displays mutagenic activity leading to viral extinction"/>
 <result pre="associated hepatocellular carcinoma [15]. 5-Fluorouracil displays mutagenic activity leading to" exact="viral" post="extinction in different RNA viruses including LCMV, VSV, EMCV,"/>
 <result pre="sequencing has recently revealed that ribavirin exerts mutagenic activity in" exact="chronic" post="HCV infected patients by facilitating G to A and"/>
 <result pre="3 µ/ml of 5-Fluorouracil and to parental levels in the" exact="absence of" post="drug. The 5-Fluorouracil resistant virus accumulated multiple mutations distributed"/>
 <result pre="µg/ml 5-Fluorouracil in Huh7D cells. All viruses grew in the" exact="absence of" post="5-Fluorouracil. As seen for HCV-5FU-1 and HCV-5FU-2, HCV-5FU-1-P6 and"/>
 <result pre="to at least parental (J6/JFH1 and HCV-RR2) levels in the" exact="absence of" post="the drug (Figure 4) and are still resistant to"/>
 <result pre="Mutations In order to find out if 5-Fluorouracil resistant viruses" exact="acquired" post="mutations, viral RNA from HCV-5FU-1-P6 and HCV-5FU-2-P6 was extracted,"/>
 <result pre="order to find out if 5-Fluorouracil resistant viruses acquired mutations," exact="viral" post="RNA from HCV-5FU-1-P6 and HCV-5FU-2-P6 was extracted, reverse transcribed,"/>
 <result pre="nucleotide 80 through nucleotide 9460. In the coding region, HCV-5FU-1-P6" exact="acquired" post="33 nucleotide substitutions (relative to HCV-RR2), 10 of which"/>
 <result pre="HCV resistant to 5-Fluorouracil. Nucleotide position* Nucleotide inHCV-RR2 Nucleotide inHCV-5FU-1-P6" exact="Protein" post="Amino-acid position*&amp;amp; Amino-acid in HCV-RR2 Amino-acid in HCV-5FU-1-P6 593"/>
 <result pre="5-Fluorouracil (Figures 3, 4, and 5). HCV-5FU resistant to 5-Fluorouracil" exact="acquired" post="synonymous and non-synonymous mutations that were distributed all along"/>
 <result pre="when compared to parental J6/JFH1 virus indicates that mechanisms and/or" exact="viral" post="RNA sequences implicated in the antiviral activity of these"/>
 <result pre="activity of these drugs could be involved in mechanism and/or" exact="viral" post="RNA sequences of the antiviral activity of ribavirin. This"/>
 <result pre="of ribavirin in interferon free regimens in the treatment of" exact="chronic" post="HCV, cross resistance of HCV to ribavirin and to"/>
 <result pre="been previously reported. When compared to its parental HCV-RR2, HCV-5FU" exact="acquired" post="33 mutations in the coding region, 10 of which"/>
 <result pre="which encoded amino-acid changes. Of note, all the 38 mutations" exact="acquired" post="by HCV-RR2 when compared to its parental J6/JFH1 [12]"/>
 <result pre="confer resistance to 5-Fluorouracil. Six of the ten non-synonymous mutations" exact="acquired" post="by HCV-5FU are located in non-structural proteins NS5a and"/>
 <result pre="structure, is located in the finger domain [42], [43]. HCV-RR2" exact="acquired" post="mutation G7710A which encodes a mutation at amino-acid 15"/>
 <result pre="mutations carried by HCV-5FU may alter its interaction with other" exact="viral" post="proteins as NS5b, critical for viral replication. Conclusion In"/>
 <result pre="its interaction with other viral proteins as NS5b, critical for" exact="viral" post="replication. Conclusion In this report, we show that a"/>
 <result pre="an interferon-free regimen containing ribavirin for the treatment of HCV" exact="infections" post="seems currently plausible. We isolated a mutant resistant to"/>
 <result pre="Palo Alto Veterans Administration Medical Center, Palo Alto, CA) [51]." exact="Infection" post="of Huh7D Cells with J6/JFH1, HCV-RR, and HCV-5FU Viruses"/>
 <result pre="the day before, and at 5 to 7 hours post" exact="infection" post="medium was replaced with 500 µl of medium containing"/>
 <result pre="the corresponding virus (in quadruplicates). At three days post infection," exact="viral" post="antigen was detected by immunofluorescence as described below. Foci"/>
 <result pre="by dividing the estimated amount of positive cells over the" exact="total" post="number of cells per well. Sequencing of Ribavirin Resistant"/>
 <result pre="number of cells per well. Sequencing of Ribavirin Resistant Viruses" exact="Viral" post="RNA was extracted from virus stocks using Trizol reagent"/>
 <result pre="3Alter H, Seeff LB (1997) Zuckermanm AZ, Thomas HC, editors." exact="Viral" post="Hepatitis. Edinburgh: Churchill Livingstone. 467–498. 4FriedMW, ShiffmanML, ReddyKR, SmithC,"/>
 <result pre="SmithC, MarinosG, et al. (2002) Peginterferon alfa-2a plus ribavirin for" exact="chronic hepatitis" post="C virus infection. N Engl J Med347: 975–982doi:;10.1056/NEJMoa020047;347/13/97512324553 5ShermanKE,"/>
 <result pre="MarinosG, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic" exact="hepatitis" post="C virus infection. N Engl J Med347: 975–982doi:;10.1056/NEJMoa020047;347/13/97512324553 5ShermanKE,"/>
 <result pre="al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C" exact="virus infection." post="N Engl J Med347: 975–982doi:;10.1056/NEJMoa020047;347/13/97512324553 5ShermanKE, FlammSL, AfdhalNH, NelsonDR,"/>
 <result pre="NelsonDR, SulkowskiMS, et al. (2011) Response-guided telaprevir combination treatment for" exact="hepatitis" post="C virus infection. N Engl J Med365: 1014–1024doi:10.1056/NEJMoa101446321916639 6LimayeAR,"/>
 <result pre="et al. (2011) Response-guided telaprevir combination treatment for hepatitis C" exact="virus infection." post="N Engl J Med365: 1014–1024doi:10.1056/NEJMoa101446321916639 6LimayeAR, DraganovPV, CabreraR (2011)"/>
 <result pre="Engl J Med365: 1014–1024doi:10.1056/NEJMoa101446321916639 6LimayeAR, DraganovPV, CabreraR (2011) Boceprevir for" exact="chronic" post="HCV genotype 1 infection. N Engl J Med365: 176–178doi:#10.1056/NEJMc1105515#SA1"/>
 <result pre="tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in" exact="hepatitis" post="C. Hepatology. 55: 749–758doi:10.1002/hep.24744 8ZeuzemS, AsselahT, AngusP, ZarskiJP, LarreyD,"/>
 <result pre="201335, polymerase inhibitor BI 207127, and ribavirin in patients with" exact="chronic" post="HCV infection. Gastroenterology 1412047–2055: S0016–5085(11)01248-0doi:10.1053/j.gastro.2011.08.051 9ChungRT, GaleMJr, PolyakSJ, LemonSM,"/>
 <result pre="al. (2008) Mechanisms of action of interferon and ribavirin in" exact="chronic hepatitis" post="C: Summary of a workshop. Hepatology47: 306–320.18161743 10FeldJJ, LutchmanGA,"/>
 <result pre="(2008) Mechanisms of action of interferon and ribavirin in chronic" exact="hepatitis" post="C: Summary of a workshop. Hepatology47: 306–320.18161743 10FeldJJ, LutchmanGA,"/>
 <result pre="Gastroenterology139: 154–162.20303352 11LindenbachBD, EvansMJ, SyderAJ, WolkB, TellinghuisenTL, et al. (2005)" exact="Complete" post="replication of hepatitis C virus in cell culture. Science309:"/>
 <result pre="EvansMJ, SyderAJ, WolkB, TellinghuisenTL, et al. (2005) Complete replication of" exact="hepatitis" post="C virus in cell culture. Science309: 623–626.15947137 12FeigelstockDA, MihalikKB,"/>
 <result pre="cell culture. Science309: 623–626.15947137 12FeigelstockDA, MihalikKB, FeinstoneSM (2011) Selection of" exact="hepatitis" post="C virus resistant to ribavirin. Virol J 8402: 1743–422X-8-402doi:10.1186/1743-422X-8-402"/>
 <result pre="ribavirin. Virol J 8402: 1743–422X-8-402doi:10.1186/1743-422X-8-402 13FeigelstockDA, MihalikKB, KaplanG, FeinstoneSM (2010)" exact="Increased" post="susceptibility of Huh7 cells to HCV replication does not"/>
 <result pre="survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced" exact="hepatocellular carcinoma." post="J Gastroenterol42: 845–853doi:10.1007/s00535-007-2099-817940838 16MorenoH, TejeroH, de la TorreJC, DomingoE,"/>
 <result pre="TorreJC, DomingoE, MartinV (2012) Mutagenesis-mediated virus extinction: virus-dependent effect of" exact="viral" post="load on sensitivity to lethal defection. PLoS One 7e32550:"/>
 <result pre="862869–2873: JVI.05712–11doi:10.1128/JVI.05712-11 19AiraksinenA, ParienteN, Menendez-AriasL, DomingoE (2003) Curing of foot-and-mouth" exact="disease" post="virus from persistently infected cells by ribavirin involves enhanced"/>
 <result pre="(2001) Ribavirin induces error-prone replication of GB virus B in" exact="primary" post="tamarin hepatocytes. J Virol75: 8074–8081.11483752 22SeversonWE, SchmaljohnCS, JavadianA, JonssonCB"/>
 <result pre="MorelV, WychowskiC, et al. (2007) Effect of ribavirin on the" exact="hepatitis" post="C virus (JFH-1) and its correlation with interferon sensitivity."/>
 <result pre="Ther12: 805–813.17713164 24ContrerasAM, HiasaY, HeW, TerellaA, SchmidtEV, et al. (2002)" exact="Viral" post="RNA mutations are region specific and increased by ribavirin"/>
 <result pre="are region specific and increased by ribavirin in a full-length" exact="hepatitis" post="C virus replication system. J Virol76: 8505–8517.12163570 25HofmannWP, PoltaA,"/>
 <result pre="MihmU, KronenbergerB, et al. (2007) Mutagenic effect of ribavirin on" exact="hepatitis" post="C nonstructural 5B quasispecies in vitro and during antiviral"/>
 <result pre="YokosukaO, ImazekiF, TanakaM, ShinoY, et al. (2004) Inhibition of subgenomic" exact="hepatitis" post="C virus RNA in Huh-7 cells: ribavirin induces mutagenesis"/>
 <result pre="in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J" exact="Viral" post="Hepat11: 479–487.15500548 27LutchmanG, DanehowerS, SongBC, LiangTJ, HoofnagleJH, et al."/>
 <result pre="SongBC, LiangTJ, HoofnagleJH, et al. (2007) Mutation rate of the" exact="hepatitis" post="C virus NS5B in patients undergoing treatment with ribavirin"/>
 <result pre="Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of" exact="hepatitis" post="C virus genotype 1-infected patients. J Virol 876172–6181: JVI.02778–12doi:10.1128/JVI.02778-12"/>
 <result pre="JacobsonI, GeorgeS (2008) Recent progress in the development of selected" exact="hepatitis" post="C virus NS3.4A protease and NS5B polymerase inhibitors. Current"/>
 <result pre="(2004) First clinical results for a novel antiviral treatment for" exact="hepatitis" post="C: a phase I/III dose escalation trial assessing tolerance,"/>
 <result pre="HCV-1 infection, including revious interferon failures. 55th AnnualMeeting of the" exact="American" post="Association for the Study of LiverDiseases October 29-November 2;"/>
 <result pre="multiple, ascending, oral doses in patients with HCV Genotype 1" exact="infection" post="who have failed prior interferon therapy. 58th Annual Meeting"/>
 <result pre="have failed prior interferon therapy. 58th Annual Meeting of the" exact="American" post="Association for the Study ofLiver Diseases (AASLD) November 2–6;"/>
 <result pre="Annual Meeting of the American Association for the Study ofLiver" exact="Diseases" post="(AASLD) November 2–6; Boston, MA, USA: 2007. 35CarrollSS, KoeplingerK,"/>
 <result pre="efficacy upon administration of a HepDirect prodrug of 2′-C-methylcytidine to" exact="hepatitis" post="C virus-infected chimpanzees. Antimicrob Agents Chemother 553854–3860: AAC.01152–10doi:10.1128/AAC.01152-10 36Le"/>
 <result pre="Antimicrob Agents Chemother 503444–3446: 50/10/3444doi:10.1128/AAC.00372-06 38MaagD, CastroC, HongZ, CameronCE (2001)" exact="Hepatitis" post="C virus RNA-dependent RNA polymerase (NS5B) as a mediator"/>
 <result pre="YoungKC, LaiMM (2003) Mutagenic and inhibitory effects of ribavirin on" exact="hepatitis" post="C virus RNA polymerase. Biochemistry42: 10462–10471.12950173 40SierraM, AiraksinenA, Gonzalez-LopezC,"/>
 <result pre="10462–10471.12950173 40SierraM, AiraksinenA, Gonzalez-LopezC, AgudoR, AriasA, et al. (2007) Foot-and-mouth" exact="disease" post="virus mutant with decreased sensitivity to ribavirin: implications for"/>
 <result pre="al. (1999) Crystal structure of the RNA-dependent RNA polymerase from" exact="hepatitis" post="C virus reveals a fully encircled active site. Nature"/>
 <result pre="Crystal structures of the RNA-dependent RNA polymerase genotype 2a of" exact="hepatitis" post="C virus reveal two conformations and suggest mechanisms of"/>
 <result pre="(2006) Quasispecies diversity determines pathogenesis through cooperative interactions in a" exact="viral" post="population. Nature439: 344–348.16327776 46TellinghuisenTL, MarcotrigianoJ, GorbalenyaAE, RiceCM (2004) The"/>
 <result pre="344–348.16327776 46TellinghuisenTL, MarcotrigianoJ, GorbalenyaAE, RiceCM (2004) The NS5A protein of" exact="hepatitis" post="C virus is a zinc metalloprotein. J Biol Chem"/>
 <result pre="EggerD, LohmannV, BartenschlagerR, BlumHE, et al. (2003) Identification of the" exact="hepatitis" post="C virus RNA replication complex in Huh-7 cells harboring"/>
 <result pre="protein into nonstructural protein 5A allows direct visualization of functional" exact="hepatitis" post="C virus replication complexes. J Virol78: 7400–7409.78/14/7400doi:10.1128/JVI.78.14.7400-7409.200415220413 49MacdonaldA, HarrisM"/>
 <result pre="C virus replication complexes. J Virol78: 7400–7409.78/14/7400doi:10.1128/JVI.78.14.7400-7409.200415220413 49MacdonaldA, HarrisM (2004)" exact="Hepatitis" post="C virus NS5A: tales of a promiscuous protein. J"/>
 <result pre="al. (1995) Comparison of full-length sequences of interferon-sensitive and resistant" exact="hepatitis" post="C virus 1b. Sensitivity to interferon is conferred by"/>
 <result pre="Clin Invest96: 224–230doi:10.1172/JCI1180257542279 51HsuHH, DonetsM, GreenbergHB, FeinstoneSM (1993) Characterization of" exact="hepatitis" post="C virus structural proteins with a recombinant baculovirus expression"/>
</results>
